Amsterdam Infection and Immunity Institute, Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Medical Library, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
JAMA Intern Med. 2020 Apr 1;180(4):561-571. doi: 10.1001/jamainternmed.2020.0009.
Acid suppressants inhibit gastric acid secretion and disrupt the intestinal microbiome. Whether acid suppression increases the risk of colonization with multidrug-resistant microorganisms (MDROs) is unclear.
To systematically examine the association of use of acid suppressants with the risk of colonization with MDROs and to perform a meta-analysis of current evidence.
PubMed, Embase, the Web of Science Core Collection, and the Cochrane Central Register of Controlled Trials were searched from database inception through July 8, 2019.
Study selection was performed independently by 2 authors (R.P.J.W. and C.M.J.E.V.-G.) on the basis of predefined selection criteria; conflicts were resolved by consensus or by an adjudicator (K.v.D.). Human observational studies (case control, cohort, and cross-sectional) and clinical trial designs were selected if they quantified the risk of MDRO colonization in users of acid suppressants in comparison with nonusers.
The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) and Meta-analysis of Observational Studies in Epidemiology (MOOSE) recommendations were followed. Data were extracted independently by the same 2 authors, and adjudication was conducted when necessary. Risk of bias was assessed according to a modified Newcastle-Ottawa Scale. Pooled odds ratios (ORs) were estimated using random-effects models; heterogeneity was evaluated using the I2 method.
The primary outcome measure was intestinal colonization with MDROs of the Enterobacterales order (producing extended-spectrum β-lactamases, carbapenemases, or plasmid-mediated AmpC β-lactamases), vancomycin-resistant enterococci, methicillin-resistant or vancomycin-resistant Staphylococcus aureus, or multidrug-resistant Pseudomonas or Acinetobacter species.
A total of 26 observational studies including 29 382 patients (11 439 [38.9%] acid suppressant users) met the selection criteria. Primary meta-analysis of 12 studies including 22 305 patients that provided adjusted ORs showed that acid suppression increased the odds of intestinal carriage of MDROs of the Enterobacterales order and of vancomycin-resistant enterococci by roughly 75% (OR = 1.74; 95% CI, 1.40-2.16; I2 = 68%). The odds were concordant with the secondary pooled analysis of all 26 studies (OR = 1.70; 95% CI, 1.44-1.99; I2 = 54%). Heterogeneity was partially explained by variations in study setting and the type of acid suppression.
Acid suppression is associated with increased odds of MDRO colonization. Notwithstanding the limitations of observational studies, the association is plausible and is strengthened by controlling for confounders. In view of the global increase in antimicrobial resistance, stewardship to reduce unnecessary use of acid suppressants may help to prevent MDRO colonization.
酸抑制剂抑制胃酸分泌并破坏肠道微生物群。胃酸抑制是否会增加对多药耐药微生物(MDRO)定植的风险尚不清楚。
系统评估酸抑制剂的使用与 MDRO 定植风险之间的关系,并对现有证据进行荟萃分析。
从数据库创建到 2019 年 7 月 8 日,在 PubMed、Embase、Web of Science 核心合集和 Cochrane 对照试验中心注册库中进行了检索。
由 2 位作者(R.P.J.W.和 C.M.J.E.V.-G.)根据预先确定的选择标准独立进行研究选择;如有冲突,通过共识或仲裁者(K.v.D.)解决。如果定量分析了酸抑制剂使用者与非使用者相比,MDRO 定植的风险,则选择人类观察性研究(病例对照、队列和横断面)和临床试验设计。
遵循系统评价和荟萃分析的首选报告项目(PRISMA)和观察性研究荟萃分析(MOOSE)建议。由同 2 位作者独立提取数据,如果有必要,将进行裁决。根据改良的纽卡斯尔-渥太华量表评估偏倚风险。使用随机效应模型估计汇总优势比(OR);使用 I2 方法评估异质性。
主要结局指标是肠内定植多药耐药肠杆菌科(产超广谱β-内酰胺酶、碳青霉烯酶或质粒介导的 AmpC β-内酰胺酶)、万古霉素耐药肠球菌、耐甲氧西林或万古霉素的金黄色葡萄球菌或多药耐药铜绿假单胞菌或不动杆菌属物种。
共有 26 项观察性研究纳入了 29382 名患者(11439 名[38.9%]酸抑制剂使用者),符合选择标准。对包括 22305 名患者的 12 项研究进行的主要荟萃分析显示,酸抑制使肠内携带 MDRO 的肠杆菌科和耐万古霉素肠球菌的几率增加了大约 75%(OR=1.74;95%CI,1.40-2.16;I2=68%)。该结果与对所有 26 项研究的二次汇总分析一致(OR=1.70;95%CI,1.44-1.99;I2=54%)。研究设置和酸抑制类型的差异部分解释了异质性。
酸抑制与 MDRO 定植的几率增加有关。尽管观察性研究存在局限性,但这种关联是合理的,并且通过控制混杂因素得到了加强。鉴于全球抗菌药物耐药性的增加,减少不必要的酸抑制剂使用的管理措施可能有助于防止 MDRO 定植。